

1652



www.pearsoned.com

Group Art Unit: 1652

Attorney
Docket: 01/22781

Examiner: Richard G. Hutson

INFORMATION DISCLOSURE STATEMENT

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

This Information Disclosure Statement is being submitted after the mailing of a substantive Office Action and a fee of \$180.00 is due. Please charge Deposit Account No. 50-1407 the required sum of \$180.00.

Sol Sheinbein
Registration No. 25,457

Date: August 14, 2003



SEP 22 2003

INTELLECTUAL PROPERTY OFFICE

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/988,113
Filing Date	March 1, 1999
First Named Inventor	Pecker et al
Group Art Unit	1652
Examiner Name	Hutson, Richard G.
Attorney Docket Number	01/22781

Sheet	1	of	3	Attorney Docket Number	01/22781
-------	---	----	---	------------------------	----------

[illegible]

Examiners Initials	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AV		WO	95/04158		Hoogwerf et al	02-09-1995		
Examiner Signature						Date Considered		

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/988,113
(use as many sheets as necessary)		Filing Date	March 1, 1999
		First Named Inventor	Pecker et al
		Group Art Unit	1652
		Examiner Name	Hutson, Richard G.
Sheet	2	of	3
		Attorney Docket Number	01/22781
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RW		Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Rev. in Biochemistry and Mol. Biology</i> , 30(5):387-444, 1995	
		Linhardt et al, "Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , 12:135-176, 1986	
		Kosir et al, "Human Prostrate Carcinoma Cells Produce Extracellular Heparanase", <i>J. Surgical Res.</i> , 67:98-105, 1997	
		Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem.</i> , 327:917-923, 1997	
		DeVouge et al, "Immunoselection of GRP94/Endoplasmic from a KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56:286-294, 1994	
		Marchetti et al, "Neutrophil Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Cancer Research</i> , 56:2856-2863, 1996	
		Marchetti et al, "Neutrophil Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Advances in Enzyme Regulation</i> , 37:111-134, 1997	
		Jin et al, Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45:1088-1095, 1990	
		Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", <i>J. Biol. Chem.</i> , 274(42):29587-29590, 1999	
		Toyoshima et al, "Human Heparanase", <i>J. Biol. Chem.</i> , 274(34):24153-24160, 1999	
		Hoogewerf et al, "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7):3268-3277, 1995	
		Freeman et al, "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", <i>Biochem. J.</i> , 342:361-368, 1999	
		Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7):793802, 1999	
		Hulet et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7):803-809, 1999	
		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from "The Protein Folding Problem and Tertiary Structure Prediction", Merz and LeGrand, Eds., Birkäuser, Boston, 1994	
		Oldberg et al, Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> , 19:5755-5762, 1980	
RW		Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", <i>Biochem. and Biophysical Res. Comm.</i> , 261:183-187, 1999	
Examiner Signature			Date Considered 12/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to the collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/988,113
		Filing Date	March 1, 1999
		First Named Inventor	Pecker et al
		Group Art Unit	1652
		Examiner Name	Hutson, Richard G.
Sheet	3	of	3
Attorney Docket Number 01/22781			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PT		Walch et al, Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", <i>Int. J. Cancer</i> , 82:112-120, 1999	
		Okamoto et al, "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6):560-564, 1998 (abstract only)	
		Zhou et al, "A 182 bp Fragment of the Mouse pro α 1(1) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", <i>J. Cell Science</i> , 108:3677-3684, 1995	
		Hormuzdi et al, "A Gene-Targeting Approach Identifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", <i>Mol. Cell Biol.</i> , 18(6):3368-3375, 1998 (abstract Only)	
		Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene", <i>Mol Cells</i> , 8(3):259-265, 1998 (abstract only)	
		Chow et al, "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", <i>Proc. Nat. Acad. Sci. USA</i> , 94:14695-14700, 1997	
		Gottschalk et al, "Somatic Gene Therapy. Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11):1111-1120, 1998 (Abstract only)	
		Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", <i>Molecular Medicine Today</i> , Oct. 1998, pp 431-437	
		Lai et al, "Homologous Recombination Based Gene Therapy", <i>Exp Nephrol</i> , 7(1):11-14, 1999 (abstract only)	
		Yazaki et al, "The structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissue", <i>Biochimica et Biophysica Acta</i> , 1172:37-42, 1993	
		Le Fur et al, "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", <i>Proc. Natl. Acad. Sci. USA</i> , 94:5332-5337, 1997	
		Guriec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary N0M0 Breast Carcinomas", <i>Breast Cancer Res Treat</i> , 44(3):261-268, 1997	
		Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects", <i>Blood</i> , 92(3):712-736, 1998	
		Hida et al, "Antisense ELAF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", <i>Am J Pathol</i> , 50(6):2125-2132, 1997 (abstract only)	
		Shastry, BS, "Gene Disruption in Mice: Models of Development and Disease", <i>Molecular and Cellular Biochemistry</i> , 181:163-179, 1998	
RF		Carpentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", <i>Clinical Cancer Research</i> , 4:2819-2824, 1998	
		Lai, et al, "DNA Vaccines", <i>Critical Reviews in Immunology</i> , 18:449-484, 1998	
Examiner Signature		Date Considered	12/18/03

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.